Evidence map›Paper›PMID 38830117›Full record

ArticleChemMedChem2024

Self-Assembling Peptide-Based High-Relaxivity Targeted MRI Contrast Agents.

Andrew M O'Brien, Griffin C Pileski, Matthew P Henry, Dana Q M Soika, Alex W Deutsch, Joseph P Hornak, Hans F Schmitthenner

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ChemMedChem, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Andrew M O'BrienSchool of Chemistry and Materials Science, Rochester Institute of Technology, Rochester, NY-14623.
Griffin C PileskiSchool of Chemistry and Materials Science, Rochester Institute of Technology, Rochester, NY-14623.
Matthew P HenrySchool of Chemistry and Materials Science, Rochester Institute of Technology, Rochester, NY-14623.
Dana Q M SoikaSchool of Chemistry and Materials Science, Rochester Institute of Technology, Rochester, NY-14623.
Alex W DeutschSchool of Chemistry and Materials Science, Rochester Institute of Technology, Rochester, NY-14623.
Joseph P HornakSchool of Chemistry and Materials Science, Rochester Institute of Technology, Rochester, NY-14623.ORCID https://orcid.org/0000-0003-1016-9849
Hans F SchmitthennerSchool of Chemistry and Materials Science, Rochester Institute of Technology, Rochester, NY-14623.ORCID https://orcid.org/0000-0002-6972-6497

Funding

High Relaxivity PSMA-Targeted Contrast Agents for MRI of Prostate CancerR15CA219915 · NCI · ROCHESTER INSTITUTE OF TECHNOLOGY · PI SCHMITTHENNER, HANS F. · 2018 to 2020
$570k
Molecularly Targeted Probes for Photodynamic Therapy and Imaging of Breast CancerR15CA260420 · NCI · ROCHESTER INSTITUTE OF TECHNOLOGY · PI SCHMITTHENNER, HANS F. · 2022 to 2023
$488k
Targeted Molecular Agents for Photoacoustic Imaging of Prostate CancerR15CA192148 · NCI · ROCHESTER INSTITUTE OF TECHNOLOGY · PI SCHMITTHENNER, HANS F. · 2014 to 2014
$444k
NCI NIH HHS R15 CA192148NCI NIH HHS R15 CA219915NCI NIH HHS R15 CA260420NIH - NCI 1-R15CA192148-01NIH - NCI 1-R15CA219915-01RIT College of ScienceRIT Fred L. Emerson FoundationRIT Honors Program
6 · The paper itself

Abstract

Concentration-dependent increases in relaxivity (r1) were found to be induced by self-assembly when Fmoc is adjacent to tryptophan in peptide-based MRI contrast agents featuring Gd-DOTA. A series of di- and tri-peptides were synthesized to test the effect of ionic strength, N-terminal substituent, peptide length, net charge, and relative location of Fmoc and tryptophan on r1 and critical aggregation concentration (CAC) at 1.0 Tesla. Compared to nominal r1 values of 3.5-7.4 mM

Indexed as

Contrast MediaMagnetic Resonance ImagingPeptidesHeterocyclic CompoundsHumansOrganometallic CompoundsContrast Mediagadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetateHeterocyclic CompoundsOrganometallic CompoundsPeptidescancerMRIpeptideself-assemblytargeting

Identifiers

PMID38830117
PMCPMC12483626

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.